By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Increased use of its ResponseDx genetic tests drove up Response Genetics' first-quarter revenues 59 percent year over year, the company said today.

The Los Angeles-based cancer molecular diagnostic test developer said that for the three months ended March 31, revenues increased to $5.9 million from $3.7 million, in part due to an 82 percent increase in revenues associated with its ResponseDx tests for colon, lung, and gastric cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.